These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
624 related articles for article (PubMed ID: 29405227)
1. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB). Wessels AM; Dowsett SA; Sims JR J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227 [TBL] [Abstract][Full Text] [Related]
2. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data. Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978 [TBL] [Abstract][Full Text] [Related]
3. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial. Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944 [TBL] [Abstract][Full Text] [Related]
4. Minimal clinically important difference in Alzheimer's disease: Rapid review. Muir RT; Hill MD; Black SE; Smith EE Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021 [TBL] [Abstract][Full Text] [Related]
5. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. Podhorna J; Krahnke T; Shear M; Harrison JE; Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820 [TBL] [Abstract][Full Text] [Related]
6. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease. Lansdall CJ; McDougall F; Butler LM; Delmar P; Pross N; Qin S; McLeod L; Zhou X; Kerchner GA; Doody RS J Prev Alzheimers Dis; 2023; 10(1):9-18. PubMed ID: 36641605 [TBL] [Abstract][Full Text] [Related]
7. Validation study of the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimer's disease. Nogueira J; Freitas S; Duro D; Almeida J; Santana I Clin Neuropsychol; 2018; 32(sup1):46-59. PubMed ID: 29566598 [TBL] [Abstract][Full Text] [Related]
8. Psychometric Properties of the Clinical Dementia Rating - Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. McDougall F; Edgar C; Mertes M; Delmar P; Fontoura P; Abi-Saab D; Lansdall CJ; Boada M; Doody R J Prev Alzheimers Dis; 2021; 8(2):151-160. PubMed ID: 33569561 [TBL] [Abstract][Full Text] [Related]
9. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761 [TBL] [Abstract][Full Text] [Related]
10. Validation study of the Alzheimer's Disease Assessment Scale-Cognitive Subscale for people with mild cognitive impairment and Alzheimer's disease in Chinese communities. Yang H; Cheng Z; Li Z; Jiang Y; Zhao J; Wu Y; Gu S; Xu H Int J Geriatr Psychiatry; 2019 Nov; 34(11):1658-1666. PubMed ID: 31347192 [TBL] [Abstract][Full Text] [Related]
11. Remote neuropsychological assessment of elderly Japanese population using the Alzheimer's Disease Assessment Scale: A validation study. Yoshida K; Yamaoka Y; Eguchi Y; Sato D; Iiboshi K; Kishimoto M; Mimura M; Kishimoto T J Telemed Telecare; 2020; 26(7-8):482-487. PubMed ID: 31068063 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA; Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517 [TBL] [Abstract][Full Text] [Related]
13. The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review. Kueper JK; Speechley M; Montero-Odasso M J Alzheimers Dis; 2018; 63(2):423-444. PubMed ID: 29660938 [TBL] [Abstract][Full Text] [Related]
14. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment]. Papp E; Pákáski M; Drótos G; Kálmán J Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337 [TBL] [Abstract][Full Text] [Related]
15. Reliability and concurrent validity of Alzheimer's disease assessment scale - Cognitive subscale, Chinese version (ADAS-Cog-C) among Chinese community-dwelling older people population. Jiang Y; Yang H; Zhao J; Wu Y; Zhou X; Cheng Z Clin Neuropsychol; 2020 Dec; 34(sup1):43-53. PubMed ID: 32279575 [TBL] [Abstract][Full Text] [Related]
16. Normative Data of Mini-Mental State Examination, Montreal Cognitive Assessment, and Alzheimer's Disease Assessment Scale-Cognitive Subscale of Community-Dwelling Older Adults in Taiwan. Wei YC; Chen CK; Lin C; Chen PY; Hsu PC; Lin CP; Shyu YC; Huang WY Dement Geriatr Cogn Disord; 2022; 51(4):365-376. PubMed ID: 35820405 [TBL] [Abstract][Full Text] [Related]
17. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. De Jesus Moreno Moreno M Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119 [TBL] [Abstract][Full Text] [Related]
18. Validity of the Clinical Dementia Rating Scale Sum of Boxes in Staging and Detection of Cognitive Impairment in Mexican Americans. Julayanont P; DeToledo JC J Geriatr Psychiatry Neurol; 2022 Jan; 35(1):128-134. PubMed ID: 33261535 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255 [TBL] [Abstract][Full Text] [Related]